Massimo Papale

CEO & Co-Founder

ModiQuant Technology

Innovative assessment of modified proteins

Our Milestones

Patent application for R/pR test

Establishment

January 2016

March 2016

June2016

July2016

Keep Calm & Startup Foggia Prize

Social Innovation award

October2016

Operative Unit

1° prizeHeroes 2017

September2017

Patent application for ModiQuant

Technology

Late diagnosis

17.5 M*

New cases

2015

22 M **

New cases

2030

8.7 M *

Deaths

Cancer is the second cause of death in the world

The Problem

Tumor markers

are poor sensitive

and not specific

Diagnostic exams

are invasive and

expensive

*Global Burden of Disease project – WHO**International Agency for Research on Cancer (IARC)

Adapted from : JSM Biotechnol Bioeng (2017)

FLUIDIA’S GOAL

Variable Diagnostic Power• Breast Cancer: 70%• Lung cancer : < 30%

Increased diagnostic and prognostic power

New perspectives in cancer diagnostics

ModiQuant approach

A new replicable and scalable method based on the use of recombinant hybrid peptides that is

Setup of IVDs test Quantitative analysis of

intracellular signalling

Characterization of drugs’

targets

And useful for

Our First product: The R-pR test

The R/pR test: a miniaturizable “sandwich”

immunoassay specifically designed to assess quantitatively and in

parallel both native and phosphorylated form of Raf Kinase Inhibitor Protein

(RKIP)

Our First product: The R-pR test

Lung CancerRenal Cancer

EBC Breast biopsy UrineFaeces

Breast Cancer Colon Cancer

POTENTIAL

APPLICATIONS Early diagnosis and

prognosis of specificcancer types in more than

500 M patients

at risk

Total IVDs market

78 Billions $

Source : Kalorama analytics 2016

The Market

Total Addressable Market (TAM) 21 M$ (0.26%)

IVDs market

(Cancer)

8 Billions $

R/pR test

On-line selling

Distributors Hospitals / Pharmacies

-GO to MARKET-

2022

2022

• R/pR test optimization

• Clinical trials

• POCT development

• Patent extension

• Marketing

20182019

2020

Screening

54.000 patients

Screening

163.000 patients

Screening

319.000 patients

2021

Timeline

Production & SellingR&D

Team & Partnership

Massimo Papale,

Biologist, PhDCEO &

Co-Founder

Elena Ranieri,

Biologist, PhDCo-Founder

R. Quitadamo

F. Pesce,

Nephrologist –Bioinformatics

E. Montemurno,

Biologist

F. Vincenti,

Product designer & Enterpreuner

G. Lucarelli,

Urologist

V. Mezzolla

Biologist

R&D

A. Giusto

Project

ManagementSocial Media

Marketing

Competitors & drivers of

Competitive AdvantageD

IAG

NO

SIS

PROGNOSIS

• Unique non-invasive test fordiagnosis and prognosis ofkidney cancer

• Patent pending scalabletechnology for the quantitativeassessment of PTM biomarkers

• ModiQuant Technology mayallow the development of a newgeneration of point of caretesting (POCT)

COST LEADERSHIP

COST FOCUS

DIFFERENTIATION

DIFFERENTIATIONFOCUS

LOWER COST DIFFERENTIATION

COMPETITIVE ADVANTAGE

BROAD

NARROW

Competitive Scope

Competitive strategy and differentiation

BUSINESS MODEL

KEYPARTNERS

• Hospitalsand

Clinicalcentersforclinical

validation• Scientific

Societis• Technological

partners (SMEandResearchCenters)for

R&D• Consultants

forlegalaspects andIPR

KEYACTIVITIES

• Clinical ValidationoftheR/pR test(ELISAMultipelex)

• SetupofthePointofCaretesting(POCT)forauto-diagnosis

• Scouting newbiomarkers andsetupnewIVDtest

• Custom-development ofnewIVDtest

• Production/sale

KEYRESOURCES

• Patents &Know-how;• Managerial Board

(CE0;CTO;CSM;CIO)• Projectmanagers• Socialmedia

managers /SEO/SEM• Biologists andLab

technicians• Clinicians• Productspecialsists

COSTS REVENUES

VALUEPROPOSITION

• R/pR Test;

• Long-termresearch

experience forconstant product

innovation;

• Corenetwork

withclinicandresearch units to

speed upclinicalvalidationandtechnical

improvements;

• ScalabilityandreplicabilityofModiQuant

technology forthesetupofIVDs

tests forlaboratory (ELISAMultiplex)orfor

auto-diagnostic(POCT)purposes;

• Personnel• Disposables

• IntellectualPropertyRights• MarketingandSocialmediaCommunication• Logistics• Royalties• Consultants(legalandbusinessaspects)

CUSTOMERS’RELATIONSHIPS

CUSTOMERS

• Publicandprivatelaboratories

• Hospitals• Universities• Pharmacies• Cancer

Patients• Pre-cancer

patients• Big-Pharma• BiotechSME

• Directsales

• Directsalesthroughdistributors

• On-linevendors• Directon-line

sales

• Socialmedia

Communication• Dedicated

Personal

assistance• Co-creation

• SalesofIVDtests(ELISAassaysandPOCT)• Patents’licensing

• CustomizeddevelopmentofnewtestforR&DandIVDuse

• Projectsgrants

CHANNELS

-500.000

-

500.000

1.000.000

1.500.000

2.000.000

2.500.000

3.000.000

3.500.000

2018 2019 2020 2021 2022

CashFlow

• R/pR test optimization• Clinical trials• POCT development• Patent extension• Marketing

Funding GAP

Financial forecasts

(2.000.000)

-

2.000.000

4.000.000

6.000.000

8.000.000

10.000.000

12.000.000

14.000.000

2018 2019 2020 2021 2022

Fatturato

EBITDA

EBIT

-250

-200

-150

-100

-50

0

50

100

150

2018 2019 2020 2021 2022

Returnoninvestment(ROI)

CAGR= 31,95%

Social Impact

Breakaway Study (The global burden of cancer- challenges and opportunities, The Economist, 2009)

2009 2020

+ 12 %

New

cases

Italy

Test R-pREARLY

DIAGNOSISBetter quality of life

Drastic reduction in the cost of patient management

25.000 $/year/patient (> 8 billion $/year)

Fluidia @FluidiaBiotechfluidiabiotech.com